---
title: "Quadrant Private Wealth Management LLC Sells 12,001 Shares of Pfizer Inc. $PFE"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264979034.md"
description: "Quadrant Private Wealth Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 10.1% in Q2, selling 12,001 shares, leaving it with 106,984 shares valued at $2,593,000. Other institutional investors also adjusted their holdings. Pfizer's stock opened at $24.45, with a market cap of $138.99 billion. The company reported Q3 earnings of $0.87 EPS, exceeding estimates, and announced a quarterly dividend of $0.43, yielding 7.0%. Analysts have mixed ratings on Pfizer, with price targets ranging from $26.00 to $33.00."
datetime: "2025-11-08T11:50:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264979034.md)
  - [en](https://longbridge.com/en/news/264979034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264979034.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264979034.md) | [繁體中文](https://longbridge.com/zh-HK/news/264979034.md)


# Quadrant Private Wealth Management LLC Sells 12,001 Shares of Pfizer Inc. $PFE

Quadrant Private Wealth Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 10.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,984 shares of the biopharmaceutical company's stock after selling 12,001 shares during the quarter. Quadrant Private Wealth Management LLC's holdings in Pfizer were worth $2,593,000 as of its most recent SEC filing.

-   MarketBeat Week in Review – 10/06 - 10/10

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Citizens National Bank Trust Department boosted its holdings in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares during the last quarter. Able Wealth Management LLC grew its position in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Trust Co of the South grew its position in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares in the last quarter. Finally, Charter Oak Capital Management LLC increased its holdings in shares of Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after purchasing an additional 444 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

## Pfizer Price Performance

Shares of PFE stock opened at $24.45 on Friday. The company has a market capitalization of $138.99 billion, a P/E ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. The company's 50-day simple moving average is $24.74 and its two-hundred day simple moving average is $24.35. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

-   5 Healthcare Plays Powering the Sector’s Big Comeback

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

## Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio is 100.00%.

## Wall Street Analysts Forecast Growth

-   Why AbbVie and Johnson & Johnson Could Outperform Pfizer

A number of brokerages recently commented on PFE. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday, October 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday. Sanford C. Bernstein reissued a "market perform" rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. UBS Group restated a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $28.18.

**Check Out Our Latest Stock Analysis on Pfizer**

## Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

## Featured Stories

-   Five stocks we like better than Pfizer
-   How to Profit From Growth Investing
-   OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever
-   How Can Investors Benefit From After-Hours Trading
-   2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
-   What is a Secondary Public Offering? What Investors Need to Know
-   CrowdStrike Partners With CoreWeave But Investors Sell the News

**Want to see what other hedge funds are holding PFE?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [Pfizer Inc. (PFE.US)](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors](https://longbridge.com/en/news/281219504.md)
- [E. Ohman J or Asset Management AB Purchases Shares of 140,617 Pfizer Inc. $PFE](https://longbridge.com/en/news/280283368.md)
- [Pfizer says phase 3 EV-304 clinical trial meets primary endpoint](https://longbridge.com/en/news/270005804.md)
- [EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi](https://longbridge.com/en/news/280785664.md)
- [Pfizer Says Hympavzi Reduced Bleeds by 93% Compared With On-Demand Treatment in Phase-3 Study](https://longbridge.com/en/news/268945142.md)